MARKHAM, ON, Aug. 27, 2014 /CNW/ - Nightingale Informatix
Corporation ("Nightingale" or the "Company") (TSX-V: NGH), an
application service provider (ASP) of electronic health record
(EHR) software and related services, announces its financial
results for the quarter ended June 30,
2014.
Q1 Fiscal 2015 Financial and Operational Summary
- Revenue was $3.7 million, down 1%
compared to $3.8 million in Q1 F2014,
and down 7% from $4.0 million in Q4
F2014. The variance from F2014 primarily reflects a decrease in
non-recurring revenues which was partially offset by a 9% increase
in recurring revenues.
- Gross profit was $3.3 million, or
88% of revenue, compared to $3.3
million, or 89% of revenue, in Q1 F2014 and $3.6 million, or 90% of revenue, in Q4
F2014.
- Operating Expenses, excluding stock based compensation,
depreciation and amortization costs were $2.9 million compared to $3.2 million in Q1 F2014 and $3.2 million in Q4 F2014.
- Adjusted EBITDA1 was $0.3
million, 9% of revenue, an increase of 19% from $0.1 million, or 3% of revenue, in Q1 F2014 and
down from $0.4 million or 10% of
revenue, in Q4 F2014.
- Net loss was $0.1 million
compared to a net loss of $0.8
million in Q1 F2014 and net loss of $0.6 million in Q4 F2014.
- Cash provided by operations was $1.6
million compared to cash provided by operations of
$0.2 million in Q1 F2014.
- Total deferred revenue was $5.5
million up from $4.8 million
at March 31, 2014.
- In May 2014, the Company
announced the promotion of Jamie
Cappelli to Executive Vice President of Operations and in
July 2014, the Company announced the
appointment of Ray Payette as Chief
Technology Officer.
- In July 2014, unveiled its next
generation cloud-based EHR – Nightingale EHR (Nexia).
- In August 2014, the Company
announced a commitment for an investment of $3.5 million in the form of a subordinated term
loan to fund the sales and marketing programs to capitalize on its
next generation product Nexia.
"We are at the tail-end of our transition phase. Nexia, our next
generation product, has started to attract the attention of buying
organizations and we are very encouraged by the rate of growth of
our pipeline," said Sam Chebib,
President and CEO. "We have started to shift our investment from
product development towards sales and marketing, the result of
which will start to become evident in the next few financial
periods."
Fiscal 2015 First Quarter Financial Review
The Company's results are prepared in accordance with
International Financial Reporting Standards (IFRS) and in Canadian
dollars unless otherwise stated.
Revenue for Q1 F2015 was $3.7
million, a decrease of $76,966
from $3.8 million for Q1 F2014.
This decrease was primarily due to a decrease in
non-recurring revenues which was partially offset by a 9% increase
in recurring revenues.
Recurring Revenue2 for Q1 F2015 was $2.8 million (77% of revenue), an increase of
$0.2 million, or 9%, from
$2.6 million (69% of revenue) in Q1
F2014. The increase in Recurring Revenue in Q1 was primarily
the result of an increase in revenues from the Company's
Nightingale On Demand and NightingaleEHR (Nexia) products.
For Q1 F2015, gross margin was 88% ($3.3
million gross profit) compared to 89% ($3.3 million gross profit) for Q1
F2014.
Operating expenses for Q1 F2015 decreased 7% to $2.9 million (79% of revenue), excluding charges
for stock based compensation and depreciation and amortization,
compared to operating expenses of $3.2
million (85% of revenue), excluding charges for stock based
compensation and depreciation and amortization, for Q1 F2014.
For Q1 F2015, Adjusted EBITDA was $0.3
million (9% of revenue), compared to $0.1 million (3% of revenue) in Q1 F2014.
The impact of fluctuations in the rate of exchange between the
US Dollar and Canadian Dollar on Q1 F2015 EBITDA were
negligible. The $0.1 million
gain from foreign currency in Q1 F2015 is predominantly the result
of the re-measurement of the Company's term loans (denominated in
US Dollars) into Canadian Dollars.
Included in net loss for Q1 F2015 is a financial gain of
$0.03 million. The financial
gain is related to the change in valuation of a derivative asset
that is embedded in the Company's Series B convertible
debentures.
For Q1 F2015, net loss was $61,732
compared to a net loss of $0.8
million in Q1 F2014.
Cash and cash equivalents on June 30,
2014 were $0.2 million, a
decrease of $0.4 million, or 71%,
from March 31, 2014.
At June 30, 2014, total common
shares issued and outstanding were 94,758,915.
The financial statements and MD&A will be available at
www.nightingalemd.com and filed on www.sedar.com on August 27, 2014. This press release should
be read in conjunction with Nightingale's Consolidated Financial
Statements and the accompanying Management Discussion and Analysis
for the year ended March 31,
2014.
Notice of Conference Call
Nightingale will host a
conference call on Thursday, August 28,
2014 at 8:30 a.m. Eastern Standard
Time. To access the conference call by telephone, dial (888)
231-8191 (or (647) 427-7450 for international). Please connect
approximately fifteen minutes prior to the call, and reference
conference ID 93452990 prior to the beginning of the call to ensure
participation. The conference call will be archived for replay
until Thursday, September 4, 2014. To
access the archived conference call, dial (416) 849-0833 or (855)
859-2056 and enter reference 93452990#. To listen to the conference
call replay on the internet please visit the Nightingale website
shortly after the call at www.nightingalemd.com.
Non-IFRS Financial Measures
The Company internally
measures its performance and results of initiatives through a
number of measures that are not recognized under IFRS and may not
be comparable to similar measures used by other
companies.
1. Adjusted EBITDA
Adjusted EBITDA
is a non-IFRS measure that management believes is a useful
measurement to evaluate the performance of the Company. Investors
should be cautioned, however, that Adjusted EBITDA should not be
construed as an alternative to net earnings as determined in
accordance with IFRS. The Company's method of calculating Adjusted
EBITDA may differ from the methods used by other companies and,
accordingly, it may not be comparable to similarly titled measures
used by other companies.
Adjusted EBITDA is defined as earnings before other loss
(income), interest, income taxes, depreciation, amortization,
stock-based compensation, and business acquisition, integration and
other costs. Management believes it is useful to exclude these
items as they are either non-cash expenses, items that cannot be
influenced by management in the short term, or items that do not
impact core operating performance, and Management uses this
information internally for forecasting and budgeting purposes.
The following provides a reconciliation of Adjusted EBITDA to
Loss and Comprehensive Loss:
|
|
|
|
|
|
Quarter
Ended
|
|
|
|
|
|
|
June 30,
2014
|
|
June 30,
2013
|
|
|
|
|
|
|
$
|
|
$
|
|
|
|
|
|
|
|
|
|
Loss and
Comprehensive Loss
|
|
|
(61,732)
|
|
(779,629)
|
Adjustments
for
|
|
|
|
|
|
|
Current Tax
Expense
|
|
|
12,508
|
|
2,183
|
|
Other Income
(Loss)
|
|
|
(92,048)
|
|
308,561
|
|
Interest
|
|
|
94,368
|
|
187,758
|
|
Depreciation and
Amortization
|
|
|
385,610
|
|
380,886
|
|
Stock-Based
Compensation
|
|
|
20,523
|
|
29,493
|
|
Other financing
(gain) loss
|
|
|
(29,483)
|
|
1,633
|
Adjusted
EBITDA
|
|
|
329,746
|
|
130,885
|
|
2. Recurring and Non-Recurring
Revenue
The Company has included recurring revenue and
non-recurring revenue measurements since it believes that this
information is useful to investors to evaluate its performance.
Investors should be cautioned, however, that recurring revenue and
non-recurring revenue should not be construed as an alternative to
revenue as determined in accordance with IFRS. Recurring
Revenue is comprised of utilization fees, hosting, support and
maintenance revenue, data management and transcription services and
transactional fees. Non-Recurring Revenue is comprised of
revenues generated from sales of perpetual software and systems
licenses and related training, data conversion and installation
services.
The following provides a reconciliation of Recurring Revenue and
Non-Recurring Revenue to Revenue:
|
|
|
|
|
|
|
Quarter
Ended
|
|
|
|
|
|
|
|
June 30,
2014
|
|
June 30,
2013
|
|
|
|
|
|
|
|
$
|
|
$
|
|
|
|
|
|
|
|
|
|
|
Non-Recurring
Revenue
|
|
|
|
860,687
|
|
1,166,784
|
Recurring
Revenue
|
|
|
|
2,831,528
|
|
2,602,397
|
|
|
|
|
|
|
|
3,692,215
|
|
3,769,181
|
|
About Nightingale
For more than a decade, Nightingale
(TSX-V: NGH) has been delivering innovative cloud-based Electronic
Health Record (EHR) and Practice Management solutions to healthcare
organizations across the United
States and Canada. Our goal
is to uncomplicate the day-to-day challenges of healthcare
providers. We achieve this by creating software that is truly
intuitive—minimizing training and maximizing adoption. We believe
so strongly in building easy-to-use software that we structured our
entire product team around user-centric design. Our clients are
benefiting from this focus through a well-supported and robust
solution that presents a holistic view of a person's well-being in
a simple, clean interface, so that the best health decisions can be
made. Nightingale – One Patient.
One Record.
www.nightingalemd.com
Forward Looking Statement
This press release contains "forward-looking statements" respecting
the issuance and cancellation of securities of the Company within
the meaning of applicable Canadian securities legislation.
Generally, forward-looking statements can be identified by the use
of forward- looking terminology such as "plans", "expects" or "does
not expect", "budget", "scheduled", "estimates", "forecasts",
"intends", "anticipates" or "does not anticipate", or "believes",
or variations of such words and phrases or state that certain
actions, events or results "may" ,"could", "would", "might",
"occur" or "be achieved". Forward-looking statements are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of Nightingale to be materially different from those
expressed or implied by such forward-looking statements, including
but not limited to: risks related to the speculative nature of the
medical software industry, which is affected by numerous factors
beyond Nightingale's control; the ability of Nightingale to
successfully secure customer contracts and the timing of securing
such contracts; the ability of Nightingale to complete and
successfully integrate its acquisitions on an accretive basis,
Nightingale's access to debt and capital facilities, including
compliance with current debt arrangements; the existence of present
and possible future government regulation; the significant
competition that exists in the medical software industry; the early
stage of Nightingale's business, and risks associated with early
stage companies, including uncertainty of revenues, markets and
profitability and the need to raise additional funding. All
material assumptions used in making forward-looking statements are
based on management's knowledge of current business conditions and
expectations of future business conditions and trends. Certain
material factors or assumptions applied by management in making
forward-looking statements, include without limitation, factors and
assumptions regarding future trends in healthcare spending,
economic conditions affecting Nightingale and North American
economies; Nightingale's ability to continue to fund its business,
rates of customer defaults, relationships with, and payments to
lenders, as well as Nightingale's operating cost structure.
Although Nightingale has attempted to identify important
factors that could cause actual results to differ materially from
those contained in forward-looking statements, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking
statements. Nightingale does not undertake to update any
forward-looking statements that are incorporated by reference
herein, except in accordance with applicable securities laws.
Further information on Nightingale Informatix Corporation is
available at www.sedar.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND
COMPREHENSIVE INCOME AND LOSS
Unaudited (Canadian
Dollars)
|
|
|
|
|
Quarter
Ended
|
|
Quarter
Ended
|
|
|
|
|
|
June 30,
2014
|
|
June 30,
2013
|
|
|
|
|
|
$
|
|
$
|
|
|
|
|
|
|
|
|
Revenue
|
|
3,692,215
|
|
3,769,181
|
|
|
|
|
|
|
|
|
Cost of
sales
|
|
438,229
|
|
430,820
|
|
|
|
|
|
|
|
|
Gross
profit
|
|
3,253,986
|
|
3,338,361
|
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
General and
administration
|
|
785,700
|
|
793,193
|
|
Sales and
marketing
|
|
613,287
|
|
658,037
|
|
Research and
development
|
|
752,453
|
|
1,045,510
|
|
Client
services
|
|
1,178,933
|
|
1,121,115
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,330,373
|
|
3,617,855
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
(76,387)
|
|
(279,494)
|
|
|
|
|
|
|
|
|
|
Interest
|
|
94,368
|
|
187,758
|
|
Other finance (gain)
loss
|
|
(29,483)
|
|
1,633
|
|
Foreign currency
(gain) loss
|
|
(92,048)
|
|
308,561
|
|
|
|
|
|
|
|
|
Loss before
tax
|
|
(49,224)
|
|
(777,446)
|
Current tax
expense
|
|
12,508
|
|
2,183
|
|
|
|
|
|
|
|
|
Loss and
comprehensive loss
|
|
(61,732)
|
|
(779,629)
|
|
|
|
|
|
|
|
|
Basic and diluted
loss per share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
loss per share
|
|
$
(0.00)
|
|
$
(0.01)
|
|
|
|
|
|
|
|
|
|
Weighted number of
common shares - basic and diluted
|
|
94,758,915
|
|
76,310,915
|
|
|
CONDENSED CONSOLIDATED BALANCE SHEET
Unaudited
(Canadian Dollars)
|
|
|
|
|
June 30,
2014
|
|
March 31,
2014
|
|
|
|
|
|
$
|
|
$
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
Cash and cash
equivalents
|
|
152,655
|
|
532,038
|
|
Accounts receivable
and unbilled accounts receivable
|
|
4,871,426
|
|
5,016,958
|
|
Other
receivables
|
|
294,934
|
|
82,958
|
|
Prepaid
expenses
|
|
412,184
|
|
289,379
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,731,199
|
|
5,921,333
|
Long-term
assets
|
|
|
|
|
|
Unbilled accounts
receivable
|
|
397,142
|
|
415,124
|
|
Financial derivative
asset
|
|
179,214
|
|
149,731
|
|
Property and
equipment
|
|
1,208,961
|
|
1,225,676
|
|
Intangible
assets
|
|
11,979,446
|
|
11,153,240
|
|
Goodwill
|
|
4,792,399
|
|
4,792,399
|
|
|
|
|
|
|
|
|
Total
assets
|
|
24,288,361
|
|
23,657,503
|
|
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
Line of
credit
|
|
1,000,000
|
|
1,000,000
|
|
Accounts payable and
accrued liabilities
|
|
5,558,444
|
|
5,122,303
|
|
Current portion of
deferred revenue
|
|
4,305,098
|
|
3,791,558
|
|
Current portion of
finance lease obligations
|
|
106,125
|
|
104,731
|
|
Current portion of
term loan
|
|
1,573,877
|
|
1,634,461
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,543,544
|
|
11,653,053
|
Long-term
liabilities
|
|
|
|
|
|
Term loan
|
|
958,400
|
|
1,403,557
|
|
Convertible
debentures
|
|
5,064,986
|
|
5,015,180
|
|
Deferred
revenue
|
|
1,214,831
|
|
978,015
|
|
Finance lease
obligations
|
|
22,856
|
|
82,745
|
|
|
|
|
|
|
|
|
Total
liabilities
|
|
19,804,617
|
|
19,132,550
|
|
|
|
|
|
SHAREHOLDERS
EQUITY
|
|
|
|
|
|
Capital
stock
|
|
34,177,890
|
|
34,177,890
|
|
Contributed
surplus
|
|
5,929,894
|
|
5,909,371
|
|
Equity portion of
convertible debentures
|
|
841,698
|
|
841,698
|
|
Warrants
|
|
4,407
|
|
4,407
|
|
Deficit
|
|
(36,470,145)
|
|
(36,408,413)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,483,744
|
|
4,524,953
|
|
|
|
|
|
|
|
|
Total liabilities
and shareholders equity
|
|
24,288,361
|
|
23,657,503
|
|
|
|
|
|
|
|
|
|
|
CONDENSED CONSOLIDATED STATEMENT OF CASH
FLOWS
Unaudited (Canadian Dollars)
|
|
|
|
Quarter
Ended
|
|
Quarter
Ended
|
|
|
|
|
June 30,
2014
|
|
June 31,
2013
|
|
|
|
|
$
|
|
$
|
|
|
|
|
|
|
|
Cash flow from
operating activities
|
|
|
|
|
Loss from
operations:
|
(61,732)
|
|
(779,629)
|
|
|
|
|
|
|
|
|
Adjustments
for:
|
|
|
|
|
|
Depreciation and
amortization
|
385,610
|
|
380,886
|
|
|
Amortization of
transaction costs related to debt financing
|
48,711
|
|
52,378
|
|
|
Stock based
compensation
|
20,523
|
|
29,493
|
|
|
Other financial
(gain) loss
|
(29,483)
|
|
1,633
|
|
|
Unrealized foreign
exchange (gain) loss
|
(95,950)
|
|
215,017
|
|
|
Interest
accretion
|
13,782
|
|
95,329
|
|
|
|
|
|
|
|
|
|
|
|
281,461
|
|
(4,893)
|
|
Changes in non-cash
working capital balances
|
|
|
|
|
|
Accounts receivable
and unbilled accounts receivable
|
145,532
|
|
458,383
|
|
|
Prepaid
expenses
|
(122,805)
|
|
(280,568)
|
|
|
Other
recievables
|
(211,976)
|
|
26,513
|
|
|
Other
assets
|
17,982
|
|
11,245
|
|
|
Accounts payable and
accrued liabilities
|
436,141
|
|
39,752
|
|
|
Deferred
revenue
|
750,356
|
|
(53,620)
|
Cash flows provided
by operating activities
|
1,296,691
|
|
196,812
|
|
|
|
|
|
|
|
Cash flow from
investing activities
|
|
|
|
|
Purchase of property
and equipment
|
(74,575)
|
|
(112,534)
|
|
Capitalized
development costs
|
(1,120,526)
|
|
(964,429)
|
Cash flows used in
investing activities
|
(1,195,101)
|
|
(1,076,963)
|
|
|
|
|
|
|
|
Cash flow from
financing activities
|
|
|
|
|
Costs associated with
term loan
|
|
|
(21,874)
|
|
Repayment of term
loan
|
(422,478)
|
|
(385,417)
|
|
Repayment of
convertible debentures
|
-
|
|
(1,141,000)
|
|
Repayment of capital
lease obligations
|
(58,495)
|
|
(10,216)
|
Cash flows used in
financing activities
|
(480,973)
|
|
(1,558,507)
|
|
|
|
|
|
|
|
Foreign exchange
losses on cash in foreign currency
|
-
|
|
882
|
|
|
|
|
|
|
|
Net decrease in
cash
|
(379,383)
|
|
(2,437,776)
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
|
|
|
Beginning of
period
|
532,038
|
|
3,491,780
|
|
End of
period
|
152,655
|
|
1,054,004
|
|
|
|
|
|
|
|
Interest
paid
|
$
93,474
|
|
$
187,758
|
Income taxes
paid
|
$
4,497
|
|
$
2,183
|
|
|
|
|
|
|
|
Non-cash investing
and financing activities:
|
|
|
|
|
|
|
|
|
|
|
Assets acquired under
finance lease
|
$
-
|
|
$
28,860
|
|
|
|
|
|
|
|
|
OVERALL PERFORMANCE, RESULTS OF OPERATIONS AND FINANCIAL
CONDITION
|
|
|
|
|
|
|
|
|
|
|
|
Year
|
Quarter
Ended
|
Year
|
Quarter
|
In $000's
|
Quarter
Ended
|
Ended
|
Ended
|
Ended
|
(except
per
|
Sept. 30,
|
Dec. 31,
|
March 31,
|
March 31,
|
June 30,
|
Sept. 30,
|
Dec. 31,
|
March 31,
|
March 31,
|
June 30,
|
share
data)
|
2012
|
2012
|
2013
|
2013
|
2013
|
2013
|
2013
|
2014
|
2014
|
2014
|
|
$
|
$
|
$
|
$
|
$
|
$
|
$
|
|
$
|
$
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recurring
|
2,665
|
2,625
|
2,606
|
10,601
|
2,602
|
2,794
|
2,798
|
2,817
|
11,012
|
2,832
|
Non-recurring
|
2,403
|
2,471
|
2,594
|
10,324
|
1,167
|
964
|
1,002
|
1,152
|
4,285
|
861
|
Total
|
5,068
|
5,096
|
5,200
|
20,925
|
3,769
|
3,758
|
3,800
|
3,969
|
15,297
|
3,693
|
|
|
|
|
|
|
|
|
|
|
|
Gross
Profit
|
4,570
|
4,336
|
4,736
|
18,582
|
3,338
|
3,259
|
3,360
|
3,576
|
13,534
|
3,254
|
|
|
|
|
|
|
|
|
|
|
|
Operating
|
|
|
|
|
|
|
|
|
|
|
Expenses
|
4,040
|
3,949
|
4,784
|
17,289
|
3,618
|
3,396
|
3,614
|
3,633
|
14,261
|
3,330
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
|
|
|
|
|
|
|
|
|
|
|
EBITDA
|
962
|
828
|
1,027
|
3,733
|
131
|
266
|
140
|
389
|
926
|
330
|
|
|
|
|
|
|
|
|
|
|
|
Operating
|
|
|
|
|
|
|
|
|
|
|
Income
(Loss)
|
529
|
387
|
(48)
|
1,293
|
(279)
|
(136)
|
(254)
|
(57)
|
(726)
|
(76)
|
|
|
|
|
|
|
|
|
|
|
|
Income (Loss)
and
|
|
|
|
|
|
|
|
|
|
|
Comprehesive
|
|
|
|
|
|
|
|
|
|
|
Income
(Loss)
|
624
|
227
|
893
|
1,994
|
(780)
|
(245)
|
(1,404)
|
(560)
|
(2,989)
|
(62)
|
|
|
|
|
|
|
|
|
|
|
|
Per
share
|
|
|
|
|
|
|
|
|
|
|
Basic
|
$ 0.01
|
$
-
|
$ 0.01
|
$ 0.03
|
$ (0.01)
|
$
-
|
$ (0.01)
|
$ (0.01)
|
$ (0.04)
|
$
-
|
Diluted
|
$ 0.01
|
$
-
|
$ 0.01
|
$ 0.03
|
$ (0.01)
|
$
-
|
$ (0.01)
|
$ (0.01)
|
$ (0.04)
|
$
-
|
Weighted Avg.
#
|
|
|
|
|
|
|
|
|
|
|
of Common
Shares
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
76,311
|
76,311
|
76,311
|
76,311
|
76,311
|
76,311
|
77,518
|
94,759
|
81,174
|
94,759
|
Diluted
|
90,086
|
90,083
|
92,870
|
92,882
|
76,311
|
76,311
|
77,518
|
94,759
|
81,174
|
94,759
|
|
|
|
|
|
|
|
|
|
|
|
Total
Assets
|
19,761
|
19,059
|
24,697
|
24,697
|
22,787
|
23,493
|
23,709
|
23,657
|
23,657
|
24,288
|
|
|
|
|
|
|
|
|
|
|
|
Total
Long-Term
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
8,421
|
7,861
|
9,790
|
9,790
|
9,386
|
10,083
|
7,651
|
7,479
|
7,479
|
7,261
|
|
|
|
|
|
|
|
|
|
|
|
Total
Deferred
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
6,605
|
5,913
|
5,890
|
5,890
|
5,837
|
5,473
|
5,233
|
4,770
|
4,770
|
5,520
|
SOURCE Nightingale Informatix Corporation